Naphthalene

Naphthalene

SCHEMBL1879779

c1ccc2ccccc2c1.c1ccc2nocc2c1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MAPT P10636 4/20 0.41
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
CYP2A6 P11509 1/20 0.40
ALOX12 P18054 1/20 0.40
GLA P06280 1/20 0.40
ACHE P22303 1/20 0.40
NQO2 P16083 1/20 0.39
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 2/20 0.35
GAA P10253 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP1A2 P05177 3/20 0.34
NCF1 P14598 2/20 0.34
NOS2 P35228 1/20 0.34
BACE1 P56817 1/20 0.34
CA12 O43570 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzo[C]Isoxazole SCHEMBL1833459 0.95 RAB9A (0.43) NPC1RAB9AMAPTALDH1A1HPGD
Benzo[C]Isoxazole SCHEMBL2493132 0.91 NPC1 (0.41) NPC1RAB9AMAPTALDH1A1HPGD
Biphenyl SCHEMBL3685922 0.89 NPC1 (0.44) NPC1RAB9AMAPTALDH1A1HPGD
Benzo[C]Isoxazole SCHEMBL11231055 0.85 RAB9A (0.41) NPC1RAB9AMAPTALDH1A1HPGD
Benzo[C]Isoxazole SCHEMBL22579004 0.85 NPC1 (0.41) NPC1RAB9AMAPTALDH1A1HPGD
Benzo[C]Isoxazole SCHEMBL23045175 0.85 NPC1 (0.38) NPC1RAB9AMAPTALDH1A1HPGD
Benzo[C]Isoxazole SCHEMBL18486460 0.85 RAB9A (0.38) NPC1RAB9AMAPTALDH1A1HPGD
Benzo[C]Isoxazole SCHEMBL6991289 0.80 KDM4E (0.47) NPC1RAB9AMAPTALDH1A1KDM4E
Benzo[C]Isoxazole SCHEMBL8468373 0.80 KDM4E (0.47) NPC1RAB9AMAPTALDH1A1KDM4E
Benzo[C]Isoxazole SCHEMBL30292819 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550753-B2 Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2017-01-24 US disclosed
US-9540327-B2 Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2017-01-10 US disclosed
US-9155733-B2 Use of tris-quaternary ammonium salts as pain modulating agents UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2015-10-13 US disclosed
US-8940774-B2 Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIV KENTUCKY RES FOUND (US) 2015-01-27 US disclosed
US-20140371266-A1 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIV KENTUCKY RES FOUND (US) 2014-12-18 US disclosed
US-8846937-B2 Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-09-30 US disclosed
US-8703803-B2 Tris-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors UNIV KENTUCKY RES FOUND (US) 2014-04-22 US disclosed
US-20140080866-A1 Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-03-20 US disclosed
US-8629163-B2 Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-01-14 US disclosed
US-20130030018-A1 Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIV KENTUCKY RES FOUND (US) 2013-01-31 US disclosed
US-20110105556-A1 TRIS-QUARTERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-05-05 US disclosed
US-20100173937-A1 USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-07-08 US disclosed
US-20100120857-A1 USE OF TRIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-05-13 US disclosed
US-20100113511-A1 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-05-06 US disclosed
US-20090318503-A1 BIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2009-12-24 US disclosed
US-20090143424-A1 TETRAKIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACTEYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2009-06-04 US disclosed
WO-2007149392-A1 MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY (US) 2007-12-27 WO disclosed
WO-2007094912-A2 BIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY (US) 2007-08-23 WO disclosed
WO-2007076112-A2 TRIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY (US) 2007-07-05 WO disclosed
US-20030225142-A1 Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225142-A1 Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies CHRNA4, CHRNA2, CHRNA5 NPC1 3364/4885RAB9A 2610/4885MAPT 213/4885
US-20130030018-A1 Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors CHRNA10, CHRNA5, CHRNA2 NPC1 1604/4885RAB9A 1337/4885MAPT 841/4885
US-20090318503-A1 BIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS CHRNA2, CHRNA5, CHRNA4 NPC1 1844/4885RAB9A 920/4885MAPT 640/4885
US-20100113511-A1 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors CHRNA2, CHRNA4, CHRNA5 NPC1 1516/4885RAB9A 1858/4885MAPT 913/4885
US-20140080866-A1 Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors CHRNA4, CHRNA2, CHRNA10 NPC1 2000/4885RAB9A 1262/4885MAPT 500/4885
US-20110105556-A1 TRIS-QUARTERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS CHRNA5, CHRNA10, CHRNA4 NPC1 1753/4885RAB9A 1556/4885MAPT 1141/4885
US-20140371266-A1 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors CHRNA2, CHRNA4, CHRNA5 NPC1 1554/4885RAB9A 1883/4885MAPT 948/4885
US-20100173937-A1 USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS CACNA1I, TRPA1, KCNN3 NPC1 3743/4885RAB9A 3311/4885MAPT 687/4885
US-20100120857-A1 USE OF TRIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS OPRL1, CACNA1I, CACNA1G NPC1 4446/4885RAB9A 1467/4885MAPT 1089/4885
US-20090143424-A1 TETRAKIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACTEYLCHOLINE RECEPTORS CHRNA3, CHRNA2, CHRNA4 NPC1 1624/4885RAB9A 1791/4885MAPT 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.